What Are the Commercial Risks and Formulation Challenges
Key findings from AMCs Impact of GLP-1 on Food Choices study: Seventy-eight percent of GLP-1 users are seeking smaller pack sizes for their food
A common factor in metabolic diseases like diabetes, inflammation is a key component of the body's natural immune defence mechanism to protect itself
Transitioning from solvent-intensive peptide production to modern techniques such as enzyme-based peptide synthesis and scalable oral small molecules, such as orforglipron, presents a vast opportunity to lower costs and boost profit margins
Liquid intake: It is recommended that patients using GLP-1s drink 2 to 3 L of water per day to prevent dehydration risk that can be seen with early satiety
The brand calls it a first-of-its-kind program that integrates GLP-1 medications as part of a larger preventive health program. Its website notes that patients receive personalized microdoses of GLP-1 medication, regular at-home biomarker testing and Nooms digital healthy habits platform to empower people with data, insights, personalized action plans and the motivational support to take control of their long-term wellbeing. Ahead, we break down why microdosing is resonating right now, what problem Noom says its addressing and who may be eligible